JP2017523959A - ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 - Google Patents

ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Download PDF

Info

Publication number
JP2017523959A
JP2017523959A JP2016575360A JP2016575360A JP2017523959A JP 2017523959 A JP2017523959 A JP 2017523959A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2017523959 A JP2017523959 A JP 2017523959A
Authority
JP
Japan
Prior art keywords
absent
lys
ala
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523959A5 (https=
Inventor
グレゴリー トーマス ボーン，
グレゴリー トーマス ボーン，
マーク レスリー スマイス，
マーク レスリー スマイス，
ブライアン トロイ フレデリック，
ブライアン トロイ フレデリック，
シモネ ビンク，
シモネ ビンク，
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2017523959A publication Critical patent/JP2017523959A/ja
Publication of JP2017523959A5 publication Critical patent/JP2017523959A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016575360A 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Withdrawn JP2017523959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018382P 2014-06-27 2014-06-27
US62/018,382 2014-06-27
PCT/US2015/038370 WO2015200916A2 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Publications (2)

Publication Number Publication Date
JP2017523959A true JP2017523959A (ja) 2017-08-24
JP2017523959A5 JP2017523959A5 (https=) 2019-02-28

Family

ID=54938965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575360A Withdrawn JP2017523959A (ja) 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用

Country Status (10)

Country Link
US (2) US20170313754A1 (https=)
EP (1) EP3161164A4 (https=)
JP (1) JP2017523959A (https=)
KR (1) KR20170043509A (https=)
CN (1) CN107075574A (https=)
AU (1) AU2015279571A1 (https=)
CA (1) CA2953721A1 (https=)
IL (1) IL249692A0 (https=)
SG (1) SG11201610799WA (https=)
WO (1) WO2015200916A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
JP2024513392A (ja) * 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944360B2 (ja) 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
KR20170108936A (ko) 2014-10-01 2017-09-27 프로타고니스트 테라퓨틱스, 인코포레이티드 신규한 α4β7 펩타이드 단량체 및 이량체 길항제
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
AU2017205633A1 (en) * 2016-01-08 2018-08-16 La Jolla Pharmaceutial Company Methods of administering hepcidin
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
CA3035234A1 (en) * 2016-09-06 2018-03-15 La Jolla Pharmaceutical Company Methods of treating iron overload
JP2020502169A (ja) * 2016-12-19 2020-01-23 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジンを投与する方法
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
US20200170971A1 (en) * 2017-07-18 2020-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP3749345A4 (en) * 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN114341161A (zh) 2019-07-10 2022-04-12 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
US20210061872A1 (en) * 2019-09-03 2021-03-04 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN114761013A (zh) * 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HRP20250769T1 (hr) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021263818A1 (en) 2020-04-28 2022-11-03 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
EP4142732B1 (en) 2020-04-28 2026-04-22 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
EP4143197A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用
EP4587034A1 (en) * 2022-09-15 2025-07-23 Migal Galilee Research Institute Ltd Site-specific activation of regulatory t cells
WO2025224128A1 (en) 2024-04-24 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201307390A (zh) * 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
WO2013086143A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
DK2968443T3 (da) * 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
JP2024513392A (ja) * 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物

Also Published As

Publication number Publication date
CA2953721A1 (en) 2015-12-30
EP3161164A2 (en) 2017-05-03
US20170313754A1 (en) 2017-11-02
WO2015200916A2 (en) 2015-12-30
EP3161164A4 (en) 2018-04-25
US20200017566A1 (en) 2020-01-16
KR20170043509A (ko) 2017-04-21
CN107075574A (zh) 2017-08-18
IL249692A0 (en) 2017-02-28
AU2015279571A1 (en) 2017-02-02
SG11201610799WA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
US12269856B2 (en) Hepcidin analogues and uses thereof
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
EP3570864B1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20200361992A1 (en) Conjugated hepcidin mimetics
JP2023540679A (ja) コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) Conjugated hepcidin mimetics
WO2025226506A1 (en) Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm
WO2026060110A1 (en) Dual- and tri-agonist compounds for obesity & t2dm
CN116457000A (zh) 缀合的铁调素模拟物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190328